CrossRef Trends in MASLD-related cirrhosis and liver cancer across diverse populations, 20102023 Jialin Wu, Bonan Chen, Fuda Xie, Jiahui Hu, Mingyu Liang, Yang Lyu, Peiyao Yu, Tiejun Feng, Muyang Huang, Canbin Fang, Ka Fai To, Terry Cheuk-Fung Yip, Xingxin Wang, Wei Kang Hepatology International .2026;[Epub] CrossRef Development and Validation of a Deep Learningenabled Single Breath-hold Abbreviated MRI Protocol for Hepatocellular Carcinoma Diagnosis Yunfei Zhang, Zhijun Geng, Xianling Qian, Yuyao Xiao, Ruofan Sheng, Mengsu Zeng Radiology: Artificial Intelligence .2026;[Epub] CrossRef Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in the Era of Systemic Therapies (20202025) Qi-Feng Chen, Song Chen, Xiongying Jiang, Jiongliang Wang, Ming Zhao Liver Cancer .2026
Participants receiving retatrutide lost an average of 11.5% and as much as 16.8% of their body weight after 40 weeks, far exceeding the placebo groups 2.6% reduction
This is different from alternating but addresses the same tolerance concern
These risks are why medical supervision when using GLP-1 medication is critical it ensures the drug is safe for you before you begin and allows for close monitoring during use
When questioned as to whether the weight loss might be partly due to loss of muscle, the OP wrote: My fasted weight is 234.7lbs
Review of long-term GLP-1RA trials dispelling pancreatitis/pancreatic cancer risks